Photo of Robert Sackstein,  MD, PhD

Robert Sackstein, MD, PhD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 525-5604
Fax: (617) 525-5571


rsackstein@rics.bwh.harvard.edu

Robert Sackstein, MD, PhD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Professor, Dermatology, Harvard Medical School
  • Professor, Medicine, Harvard Medical School
  • Physician Active Staff, Dermatology and Medicine, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

In early work, our laboratory identified that L-selectin expression is characteristic not only of lymphocytes but also of early hematopoietic progenitor cells, and this observation led us to examine the expression of L-selectin ligands among human bone marrow cells. These studies led to identification of an L-selectin ligand on early hematopoietic progenitor cells that is structurally distinct from L-selectin ligands expressed on endothelial cells. Subsequent biochemical studies from our laboratory revealed that this ligand, now known as Hematopoietic Cell E-/L-selectin Ligand (HCELL), is the most potent naturally-expressed E- and L-selectin ligand in the body. HCELL is a specialized glycoform of CD44 natively expressed exclusively on human hematopoietic stem cells. Through its role as a potent E-selectin ligand, HCELL functions as the "bone marrow homing receptor" that directs hematopoietic stem cell migration into the marrow. Current studies are aimed at elucidating HCELL's role in hematopoiesis and in the regulation of stem cell homing. In addition, HCELL is characteristically expressed on blasts of acute leukemia, and thus we are investigating how HCELL expression is related to leukemogenesis and how expression of this molecule is regulated on normal stem cells and leukemic blasts. In complementary studies, we have developed reagents to program HCELL expression by ex vivo glycan engineering of surface CD44 and we are examining how enforced HCELL expression licenses the delivery of adult stem cells intravascularly for regenerative therapeutics and how it affects leukemogenesis. Another focus of our laboratory is to elucidate the physiology of lymphocyte migration following hematopoietic stem cell transplantation (HSCT). We have obtained evidence that the migration of lymphocytes to lymph nodes post-HSCT is disturbed in part because of disordered regulation of lymphocyte L-selectin gene expression. We are examining the molecular basis of altered L-selectin expression, and, moreover, we are studying how pathologic tissue-specific migration patterns develop post-transplant. In particular, acute graft-versus-host disease (GVHD) following allogeneic HSCT is characterized by the directed migration of alloreactive lymphocytes into three principal target tissues - skin, liver and gut - wherein they mediate tissue destruction. Our laboratory is investigating the adhesion molecules that regulate skin-specific migration of lymphocytes in cutaneous GVHD reactions, in order to elucidate the molecular basis of this process and develop therapeutic agents to treat or prevent cutaneous GVHD. Our overall aim in these studies is to devise novel therapies to eliminate the detrimental GVHD reaction of allogeneic transplantation without disturbing beneficial immune reactions such as the graft-versus-malignancy effect. In other studies, we are investigating the structural biology of key molecules which mediate adhesive interactions that create microenvironmental "niches" for tumor cell proliferation, the adhesion molecules which allow for tumor cell dissemination, and the adhesion molecules that regulate lymphocyte trafficking to sites of tumor. The goal in these studies is to utilize structural information for the rational design of drugs that disrupt adhesion molecules critical for tumor cell growth and metastasis, and that improve immune effector cell infiltration of tumor tissue.

Publications

Powered by Harvard Catalyst
  • Abdi R, Moore R, Sakai S, Donnelly CB, Mounayar M, Sackstein R. HCELL Expression on Murine MSC Licenses Pancreatotropism and Confers Durable Reversal of Autoimmune Diabetes in NOD Mice. Stem Cells 2015. PubMed
  • Peter Y, Sen N, Levantini E, Keller S, Ingenito EP, Ciner A, Sackstein R, Shapiro SD. CD45/CD11b positive subsets of adult lung anchorage-independent cells harness epithelial stem cells in culture. 2012. PubMed
  • Sackstein R. Re: Ex Vivo Fucosylation Improves Human Cord Blood Engraftment in NOD-SCID IL-2R粒 Mice. Exp Hematol 2012. PubMed
  • Sackstein R. Glycoengineering of HCELL, the Human Bone Marrow Homing Receptor: Sweetly Programming Cell Migration. Ann Biomed Eng 2012; 40:766-76. PubMed
  • Sackstein R. Engineering cellular trafficking via glycosyltransferase-programmed stereosubstitution. Ann N Y Acad Sci 2012. PubMed
  • Jansen AJ, Josefsson EC, Rumjantseva V, Liu QP, Falet H, Bergmeier W, Cifuni SM, Sackstein R, von Andrian UH, Wagner DD, Hartwig JH, Hoffmeister KM. Desialylation accelerates platelet clearance after refrigeration and initiates GPIb留 metalloproteinase-mediated cleavage in mice. Blood 2012; 119:1263-73. PubMed
  • Jacobs PP, Sackstein R. CD44 and HCELL: Preventing hematogenous metastasis at step 1. FEBS Lett 2011; 585:3148-58. PubMed
  • Merzaban JS, Burdick MM, Gadhoum SZ, Dagia NM, Chu JT, Fuhlbrigge RC, Sackstein R. Analysis of glycoprotein E-selectin ligands on human and mouse marrow cells enriched for hematopoietic stem/progenitor cells. Blood 2011; 118:1774-83. PubMed
  • Sackstein R. The biology of CD44 and HCELL in hematopoiesis: the 'step 2-bypass pathway' and other emerging perspectives. Curr Opin Hematol 2011; 18:239-48. PubMed
  • Thankamony SP, Sackstein R. Enforced hematopoietic cell E- and L-selectin ligand (HCELL) expression primes transendothelial migration of human mesenchymal stem cells. Proc Natl Acad Sci U S A 2011; 108:2258-63. PubMed
  • Sackstein R. Hitting the sweet spot for lymphoma. Blood 2010; 115:4626-7. PubMed
  • Chester R, Sackstein R. Embryonic stem cell-based therapeutics: balancing scientific progress and bioethics. Health Matrix Clevel 2010; 20:203-17. PubMed
  • Sackstein R. Directing stem cell trafficking via GPS. Methods Enzymol 2010; 479:93-105. PubMed
  • Lee JY, Buzney CD, Poznansky MC, Sackstein R. Dynamic alterations in chemokine gradients induce transendothelial shuttling of human T cells under physiologic shear conditions. J Leukoc Biol 2009; 86:1285-94. PubMed
  • Sackstein R. Glycosyltransferase-programmed stereosubstitution (GPS) to create HCELL: engineering a roadmap for cell migration. Immunol Rev 2009; 230:51-74. PubMed
  • Sackstein R,Fuhlbrigge R. Western Blot Analysis of Adhesive Interactions under Fluid Shear Conditions: The Blot Rolling Assay. Methods Mol Biol 2009; 536:343-54. PubMed
  • Gadhoum SZ,Sackstein R. CD15 expression in human myeloid cell differentiation is regulated by sialidase activity. Nat Chem Biol 2008; 4:751-7. PubMed
  • Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J, Moreau AS, Burwick N, Azab AK, Roccaro A, Azab F, Sacco A, Farag M, Sackstein R, Ghobrial IM. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom Macroglobulinemia. Blood 2008; 112:150-8. PubMed
  • Resto VA, Burdick MM, Dagia NM, McCammon SD, Fennewald SM, Sackstein R. L-selectin-mediated lymphocyte-cancer cell interactions under low fluid shear conditions. J Biol Chem 2008; 283:15816-24. PubMed
  • Shaulov A, Yue S, Wang R, Joyce RM, Balk SP, Kim HT, Avigan DE, Uhl L, Sackstein R, Exley MA. Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: Implications for posttransplant survival. Exp Hematol 2008; 36:464-72. PubMed
  • Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, Wohlgemuth R. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008; 14:181-7. PubMed
  • Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 2007; 104:5431-6. PubMed
  • Schreiber TH, Shinder V, Cain DW, Alon R, Sackstein R. Shear flow-dependent integration of apical and subendothelial chemokines in T-cell transmigration: implications for locomotion and the multistep paradigm. Blood 2006; 109:1381-6. PubMed
  • Dagia NM, Gadhoum SZ, Knoblauch CA, Spencer JA, Zamiri P, Lin CP, Sackstein R. G-CSF induces E-selectin ligand expression on human myeloid cells. Nat Med 2006; 12:1185-90. PubMed
  • Burdick MM, Chu JT, Godar S, Sackstein R. HCELL is the major E- and L-selectin ligand expressed on LS174T colon carcinoma cells. J Biol Chem 2006; 281:13899-905. PubMed
  • Fuhlbrigge RC, King SL, Sackstein R, Kupper TS. CD43 is a ligand for E-selectin on CLA+ human T cells. Blood 2006; 107:1421-6. PubMed
  • Hanley WD, Napier SL, Burdick MM, Schnaar RL, Sackstein R, Konstantopoulos K. Variant isoforms of CD44 are P- and L-selectin ligands on colon carcinoma cells. FASEB J 2006; 20:337-9. PubMed
  • Sackstein R, Fuhlbrigge R. The blot rolling assay: a method for identifying adhesion molecules mediating binding under shear conditions. Methods Mol Biol 2006; 341:217-26. PubMed
  • Sackstein R. A Revision of Billingham's Tenets: The Central Role of Lymphocyte Migration in Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 2006; 12:2-8. PubMed
  • Sackstein R. The lymphocyte homing receptors: gatekeepers of the multistep paradigm. Curr Opin Hematol 2005; 12:444-50. PubMed
  • Hanley WD, Burdick MM, Konstantopoulos K, Sackstein R. CD44 on LS174T colon carcinoma cells possesses E-selectin ligand activity. Cancer Res 2005; 65:5812-7. PubMed
  • Dey BR, McAfee S, Colby C, Cieply K, Caron M, Saidman S, Preffer F, Shaffer J, Tarbell N, Sackstein R, Sachs D, Sykes M, Spitzer TR. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2005; 128:351-9. PubMed
  • Sackstein R. The bone marrow is akin to skin: HCELL and the biology of hematopoietic stem cell homing. J Invest Dermatol 2004; 122:1061-9. PubMed
  • Elfenbein GJ, Sackstein R. Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow. Exp Hematol 2004; 32:327-39. PubMed
  • Milinkovic M, Antin JH, Hergrueter CA, Underhill CB, Sackstein R. CD44-hyaluronic acid interactions mediate shear-resistant binding of lymphocytes to dermal endothelium in acute cutaneous GVHD. Blood 2003; 103:740-2. PubMed
  • Elfenbein GJ, Sackstein R, Oblon DJ. Do G-CSF mobilized, peripheral blood-derived stem cells from healthy, HLA-identical donors really engraft more rapidly than do G-CSF primed, bone marrow-derived stem cells? No! Blood Cells Mol Dis 2004; 32:106-11. PubMed
  • Dimitroff CJ, Kupper TS, Sackstein R. Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. J Clin Invest 2003; 112:1008-18. PubMed
  • Kraus AB, Shaffer J, Toh HC, Preffer F, Dombkowski D, Saidman S, Colby C, George R, McAfee S, Sackstein R, Dey B, Spitzer TR, Sykes M. Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol 2003; 31:609-21. PubMed
  • Daly A, McAfee S, Dey B, Colby C, Schulte L, Yeap B, Sackstein R, Tarbell NJ, Sachs D, Sykes M, Spitzer TR. Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant 2003; 9:373-82. PubMed
  • Dey BR, McAfee S, Colby C, Sackstein R, Saidman S, Tarbell N, Sachs DH, Sykes M, Spitzer TR. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation Biol Blood Marrow Transplant 2003; 9:320-9. PubMed
  • Dimitroff CJ, Bernacki RJ, Sackstein R. Glycosylation-dependent inhibition of cutaneous lymphocyte-associated antigen expression: implications in modulating lymphocyte migration to skin. Blood 2002; 101:602-10. PubMed
  • Sackstein R, Messina JL, Elfenbein GJ. In vitro adherence of lymphocytes to dermal endothelium under shear stress: implications in pathobiology and steroid therapy of acute cutaneous GVHD. Blood 2002; 101:771-8. PubMed
  • Toh HC, Spitzer TR, Preffer F, Alexander SI, McAfee S, Dombkowski D, Clark JS, Colby C, Saidman S, Sackstein R, Sykes M. Fluctuating lymphocyte chimerism, tolerance and anti-tumor response in a patient with refractory lymphoma receiving nonmyeloablative conditioning and a haploidentical related allogeneic bone marrow transplant. Cytokines Cell Mol Ther 2003; 7:43-7. PubMed
  • B. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74:1405-9. PubMed
  • B. Cryopreservation and mycophenolate therapy are detrimental to hematopoietic progenitor cells. Transplantation 2002; 74:1159-66. PubMed
  • Theodore PR, Simon AR, Warrens AN, Sackstein R, Sykes M. Porcine mononuclear cells adhere to human fibronectin independently of very late antigen-5: implications for donor-specific tolerance induction in xenotransplantation. Xenotransplantation 2002; 9:277-89. PubMed
  • Fuhlbrigge RC, King SL, Dimitroff CJ, Kupper TS, Sackstein R. Direct real-time observation of E- and P-selectin-mediated rolling on cutaneous lymphocyte-associated antigen immobilized on Western blots. J Immunol 2002; 168:5645-51. PubMed
  • B. Pig hematopoietic cell chimerism in baboons conditioned with a nonmyeloablative regimen and CD154 blockade. Transplantation 2002; 73:12-22. PubMed
  • Dimitroff CJ, Lee JY, Schor KS, Sandmaier BM, Sackstein R. differential L-selectin binding activities of human hematopoietic cell L-selectin ligands, HCELL and PSGL-1. J Biol Chem 2001; 276:47623-31. PubMed
  • Exley MA, Tahir SM, Cheng O, Shaulov A, Joyce R, Avigan D, Sackstein R, Balk SP. A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J Immunol 2001; 167:5531-4. PubMed
  • Gonz. Real-time evidence of in vivo leukocyte trafficking in human skin by reflectance confocal microscopy. J Invest Dermatol 2001; 117:384-6. PubMed
  • Alwayn IP, Buhler L, Appel JZ, Goepfert C, Csizmadia E, Correa L, Harper D, Kitamura H, Down J, Awwad M, Sackstein R, Cooper DK, Robson SC. Mechanisms of thrombotic microangiopathy following xenogeneic hematopoietic progenitor cell transplantation. Transplantation 2001; 71:1601-9. PubMed
  • Dimitroff CJ, Lee JY, Rafii S, Fuhlbrigge RC, Sackstein R. CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol 2001; 153:1277-86. PubMed
  • B. Porcine hematopoietic cell xenotransplantation in nonhuman primates is complicated by thrombotic microangiopathy. Bone Marrow Transplant 2001; 27:1227-36. PubMed
  • Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D, Poliquin C, Vanderklish J, Sachs DH, Sykes M, Spitzer TR. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant 2002; 7:604-12. PubMed
  • Dimitroff CJ, Lee JY, Fuhlbrigge RC, Sackstein R. A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells. Proc Natl Acad Sci U S A 2000; 97:13841-6. PubMed
  • B. Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates. Transplantation 2000; 70:1323-31. PubMed
  • Sackstein R, Dimitroff CJ. A hematopoietic cell L-selectin ligand that is distinct from PSGL-1 and displays N-glycan-dependent binding activity. Blood 2000; 96:2765-74. PubMed
  • B. A nonmyeloablative regimen with CD40L blockade leads to humoral and cellular hyporesponsiveness to pig hematopoietic cells in baboons. Transplant Proc 2000; 32:1100. PubMed
  • Gopfert C, Buhler L, Wise R, Basker M, Gojo S, Imai M, Alwayn I, Sachs DH, Sackstein R, Cooper DK, Robson SC. Von willebrand factor concentration, multimeric patterns, and cleaving protease activity in baboons undergoing xenogeneic peripheral blood stem cell transplantation. Transplant Proc 2000; 32:990. PubMed
  • Alwayn IP, Buhler L, Basker M, Goepfert C, Kawai T, Kozlowski T, Ierino F, Sachs DH, Sackstein R, Robson SC, Cooper DK. Coagulation/thrombotic disorders associated with organ and cell xenotransplantation. Transplant Proc 2000; 32:1099. PubMed
  • B. High-dose porcine hematopoietic cell transplantation combined with CD40 ligand blockade in baboons prevents an induced anti-pig humoral response. Transplantation 2000; 69:2296-304. PubMed
  • Colby C, Chang Q, Fuchimoto Y, Ferrara V, Murphy M, Sackstein R, Spitzer TR, White-Scharf ME, Sachs DH. Cytokine-mobilized peripheral blood progenitor cells for allogeneic reconstitution of miniature swine. Transplantation 2000; 69:135-40. PubMed
  • Toh HC, McAfee SL, Sackstein R, Multani P, Cox BF, Garcia-Carbonero R, Colby C, Spitzer TR. High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study. Bone Marrow Transplant 2000; 25:19-24. PubMed
  • Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P, Saidman S, Weyouth DW, Preffer F, Poliquin C, Foley A, Cox B, Andrews D, Sachs DH, Sykes M. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000; 6:309-20. PubMed
  • Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS, Klucher KM, Daley GQ, Kraeft SK, Sackstein R, Alyea EP, von Andrian UH, Chen LB, Gutierrez-Ramos JC, Pendergast AM, Griffin JD. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood 1999; 94:4233-46. PubMed
  • Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24:897-902. PubMed
  • Toh HC, McAfee SL, Sackstein R, Cox BF, Colby C, Spitzer TR. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 1999; 24:891-5. PubMed
  • Spitzer TR, Delmonico F, Tolkoff-Rubin N, McAfee S, Sackstein R, Saidman S, Colby C, Sykes M, Sachs DH, Cosimi AB. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68:480-4. PubMed
  • Sykes M, Preffer F, McAfee S, Saidman SL, Weymouth D, Andrews DM, Colby C, Sackstein R, Sachs DH, Spitzer TR. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353:1755-9. PubMed
  • Ballester OF, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC, Perkins JB, Sullivan DM, Rosen R, Sackstein R, Zorsky P, Saez R, Elfenbein GJ. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 1998; 20:653-6. PubMed
  • Sackstein R, Fu L, Allen KL. A hematopoietic cell L-selectin ligand exhibits sulfate-independent binding activity. Blood 1997; 89:2773-81. PubMed
  • Sackstein R. Expression of an L-selectin ligand on hematopoietic progenitor cells. Acta Haematol 1997; 97:22-8. PubMed
  • Wasik MA, Sackstein R, Novick D, Butmarc JR, Zhang Q, Vonderheid EC, Kadin ME. Cutaneous CD56+ large T-cell lymphoma associated with high serum concentration of IL-2. Hum Pathol 1996; 27:738-44. PubMed
  • Sackstein R. Lymphocyte migration following bone marrow transplantation. Ann N Y Acad Sci 1995; 770:177-88. PubMed
  • Sackstein R. Physiologic basis of steroid-induced immunosuppression. Effects on lymphocyte migration to lymph nodes. J Fla Med Assoc 1995; 82:613-5. PubMed
  • Sackstein R, Meng L, Xu XM, Chin YH. Evidence of post-transcriptional regulation of L-selectin gene expression in rat lymphoid cells. Immunology 1995; 85:198-204. PubMed
  • Sackstein R, Borenstein M. The effects of corticosteroids on lymphocyte recirculation in humans: analysis of the mechanism of impaired lymphocyte migration to lymph node following methylprednisolone administration. J Investig Med 1995; 43:68-77. PubMed
  • Oxley SM, Sackstein R. Detection of an L-selectin ligand on a hematopoietic progenitor cell line. Blood 1994; 84:3299-306. PubMed
  • Sackstein R. Adoptive Immunotherapy: The Magic Bullet of Cancer Therapy? Cancer Control 2000; 1:65-66. PubMed
  • Sackstein R. Effects of methylprednisolone administration on lymphocyte LECAM-1, CD44, and LFA-1 expression. Implications for steroid-induced lymphopenia. Ann N Y Acad Sci 1993; 696:417-9. PubMed
  • Sackstein R. Physiologic migration of lymphocytes to lymph nodes following bone marrow transplantation: role in immune recovery. Semin Oncol 1993; 20:34-9. PubMed
  • Chin YH, Sackstein R, Cai JP. Lymphocyte-homing receptors and preferential migration pathways. Proc Soc Exp Biol Med 1991; 196:374-80. PubMed
  • Chin YH, Falanga V, Streilein JW, Sackstein R. Lymphocyte recognition of psoriatic endothelium: evidence for a tissue-specific receptor/ligand interaction. J Invest Dermatol 1989; 93:82S-87S. PubMed
  • Sackstein R, Falanga V, Streilein JW, Chin YH. Lymphocyte adhesion to psoriatic dermal endothelium is mediated by a tissue-specific receptor/ligand interaction. J Invest Dermatol 1988; 91:423-8. PubMed
  • Chin YH, Falanga V, Streilein JW, Sackstein R. Specific lymphocyte-endothelial cell interactions regulate migration into lymph nodes, Peyer's patches, and skin. Reg Immunol 1988; 1:78-83. PubMed
  • Whitehead AS, Sackstein R. Molecular biology of the human and mouse MHC class III genes: phylogenetic conservation, genetics and regulation of expression. Immunol Rev 1985; 87:185-208. PubMed
  • Sackstein R, Colten HR. Molecular regulation of MHC class III (C4 and factor B) gene expression in mouse peritoneal macrophages. J Immunol 1984; 133:1618-26. PubMed
  • Chaplin DD, Sackstein R, Perlmutter DH, Weis JH, Kruse TA, Coligan J, Colten HR, Seidman JG. Expression of hemolytically active murine fourth component of complement in transfected L cells. Cell 1984; 37:569-76. PubMed
  • Sackstein R, Roos MH, Démant P, Colten HR. Subdivision of the S region of the mouse major histocompatibility complex by identification of genomic polymorphisms of the class III genes. Immunogenetics 1983; 20:321-30. PubMed
  • Sackstein R, Colten HR, Woods DE. Phylogenetic conservation of a class III major histocompatibility complex antigen, factor B. Isolation and nucleotide sequencing of mouse factor B cDNA clones. J Biol Chem 1983; 258:14693-7. PubMed
Hide